knowledge -WSS

knowledge

author：hotspot 2025-08-08 05:32:51 - browse：2

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA approves Leqembi, a milestone in Alzheimer’s treatment

WSS

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

North Korean leader's powerful sister says warplanes repelled US spy plane

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Health insurers say they are turning to AI to cut costs, improve care

Why Titanic fascinates society, still drawing tours to the wreckage

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Walensky prepares to leave CDC — and Congress — behind

The PBM ad wars are taking over Washington, D.C.

Alkermes shareholders re

How redistricting in 6 states could affect who controls Congress

Psychedelics group wrestles with new pharma identity

What to know about a major upcoming Wegovy heart health study

23andMe had bad news about my health. I wish a person had delivered it

Lab trade group sues FDA to halt regulation of lab

Activists slam private health insurers over coverage restrictions

US intelligence assessment says Iran not currently developing nuclear weapons

entertainment

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Latest bird flu infection made farmworker sicker than earlier cases

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

How corporate America is slashing DEI workers amid backlash to diversity programs

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Biohaven protein

focus

Wikipedia

focus

entertainment